New anabolic therapies in osteoporosis
Authors:
- John P BilezikianJBJohn P Bilezikian
- 1 March 2003
- journal article
- review article
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 32 (1) , 285-307
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled TrialThe Journal of Clinical Endocrinology & Metabolism, 2000
- Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical TrialJournal of Bone and Mineral Research, 1998
- The Predictive Value of Biochemical Markers of Bone Turnover for Bone Mineral Density in Early Postmenopausal Women Treated with Hormone Replacement or Calcium SupplementationThe Journal of Clinical Endocrinology & Metabolism, 1997
- Effects of Hormone Therapy on Bone Mineral DensityJAMA, 1996
- Perspective slow-release sodium fluoride in osteoporosisJournal of Bone and Mineral Research, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled TrialAnnals of Internal Medicine, 1995
- A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosisOsteoporosis International, 1991
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- Safe and Effective Treatment of Osteoporosis With Intermittent Slow Release Sodium Fluoride: Augmentation of Vertebral Bone Mass and Inhibition of Fractures*The Journal of Clinical Endocrinology & Metabolism, 1989